Idorsia
Martine Clozel is the current EVP and Chief Scientific Officer at Idorsia. Martine previously worked at GlaxoSmithKline as a Senior Sales Executive from February 2008 to June 2021.
Martine Clozel has a Bachelor of Science (B.S.) from Converse University. Martine also has certification from the American Society for Clinical Pathology (ASCP) in MT (ASCP).
They work with Andrew C. Weiss - SVP, Head of Investor Relations & Corporate Communications, Ulrich Mentzel - SVP, Head of Drug Discovery Pharmacology & Preclinical Development, and André C. Muller - EVP, CFO. Martine Clozel reports to Jean-Paul Clozel, CEO.
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.